
89bio Inc (ETNB) Stock Forecast & Price Target
89bio Inc (ETNB) Analyst Ratings
Bulls say
89bio Inc., a clinical-stage biopharmaceutical company, is making significant progress in developing pegozafermin for serious conditions such as nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), targeting a substantial market with unmet medical needs. The company has reported encouraging clinical trial results that indicate the potential efficacy of pegozafermin, which may lead to favorable regulatory outcomes and future revenue opportunities. Additionally, 89bio's strong financial position, underscored by adequate funding to support ongoing development, bolsters investor confidence and enhances its capacity to navigate the competitive landscape of biopharmaceuticals.
Bears say
89bio Inc exhibits several fundamental vulnerabilities contributing to a negative outlook on its stock. Key risks include the potential failure of its product candidate, pegozafermin, to meet projected commercial revenue estimates, which could be impacted by market size, penetration rates, and pricing strategies. Additionally, the company's ability to secure necessary capital resources for ongoing operations and commercialization efforts remains uncertain, posing further concerns for its financial stability and growth potential.
This aggregate rating is based on analysts' research of 89bio Inc and is not a guaranteed prediction by Public.com or investment advice.
89bio Inc (ETNB) Analyst Forecast & Price Prediction
Start investing in 89bio Inc (ETNB)
Order type
Buy in
Order amount
Est. shares
0 shares